KZR 616

Drug Profile

KZR 616

Alternative Names: KZR 616

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Onyx Pharmaceuticals
  • Developer Kezar Life Sciences
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Immunomodulators; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Systemic lupus erythematosus
  • Phase I Autoimmune disorders

Most Recent Events

  • 13 Jun 2018 Updated adverse events, pharmacodynamic and pharmacokinetic data from a phase I trial in Autoimmune diseases presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 07 Mar 2018 Phase-I/II clinical trials in Systemic lupus erythematosus in USA (SC) (NCT03393013)
  • 08 Jan 2018 Kezar Life Sciences plans a phase Ib/II trial for Systemic lupus erythematosus in January 2018 (NCT03393013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top